TherapeuticsMD's (TXMD) stock price has risen from a low of $3.51 in December '18 due to a combination of 1) market recovery and 2) great script count data. However, the stock price has once again remained under pressure with analysts citing: 1) lack of differentiation for Imvexxy and Bijuva, 2) emerging competition for Bijuva and 3) Annovera's launch likely to be lackluster.
Lack of differentiation for Imvexxy and Bijuva
Figure 1: Overview of Imvexxy's differentiation
Source: TXMD's JPM Presentation 2019
Being hormonal products, Imvexxy and Bijuva are chemically identical to products that exist